Atonarp takes aim at molecular diagnostics with automated, AI-driven, point-of-care tech

By Stacy Lawrence, Staff Writer, BioWorld MedTech USA, August 30, 2019 / Volume 23, No. 169

Tokyo-based Atonarp Inc. has a very clear mission, to develop automated, AI-based, miniaturized platforms for mass spectrometry and optical spectroscopy. But that sort of complex molecular analysis has a wide range of potential industry applications, making it difficult to prioritize efforts. The startup company has already commercialized the first quantitative, real-time miniaturized mass spectrometers for semiconductor and pharmaceutical industry gas detection. Its first product is geared toward monitoring pharmaceutical lyophilization, which is a freeze-drying process commonly used by the pharmaceutical industry for product stabilization, for contamination, leaks or other problems. Now, with a new cash infusion in the form of a $33 million series C round, it’s turning to focus on point-of-care diagnostics.

To read more, please connect to the source: